Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

MagForce starts research project with University of Bremen


Print article Print article
© Marketwire 2013
2013-01-31 10:12:36 -

BERLIN, GERMANY -- (Marketwire) -- 01/31/13 --


MagForce AG /
MagForce starts research project with University of Bremen
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.



* Project to develop magnetic iron oxide particles with improved
efficiency



* Agreement on funding by German Federal Ministry of Economics and
Technology from the German Mittelstand innovation program "Zentrales
Innovationsprogramm Mittelstand (ZIM)"



MagForce AG (Frankfurt, XETRA: MF6), a
leading medical technology company in the field of nanomedicine in
oncology,
today announced the start of a research project with the University of
Bremen,
Center for Environmental Research and Sustainable Technology, for the
development of magnetic iron oxid particles with improved efficiency. The
novel
particles will allow a more efficient treatment of abdominal cancers, such
as
prostate and pancreatic cancer. A more efficient magnetic fluid and a pilot
manufacturing facility will result from the collaboration.





The project will receive funding from the German Mittelstand Innovation
Program
(ZIM) which is managed by the German Federal Ministry of Economics and
Technology and will run for two years.



"We are excited to be working with Prof Dr Jorg Thöming,
who is an
internationally renowned expert in the area of process engineering,
as a
cooperation partner. This project is perfectly in-line with
MagForce's new
strategy to conduct early-stage research and development collaborations
with
academic institutions", commented Prof Dr Hoda Tawfik, COO and co-
CEO of
MagForce AG. "In August 2012, we temporarily put all internal early-
stage
research and development on hold to focus the Company's
resources on
establishing our NanoTherm® therapy in the market. This project
gives us the
opportunity to develop the next generation of NanoTherm® that will
significantly
improve the treatment of abdominal cancers." Prof Dr Jorg Thöming
comments: "I
am excited to start the collaboration in the nanotechnology area with
MagForce,
an innovative nanomedicine company. The exploitation of synergies
between our
scientists is very promising."



About MagForce AG



MagForce AG is a leading medical technology company in the field of
nanomedicine
in oncology. The Company's proprietary, NanoTherm® therapy, enables
the targeted
treatment of solid tumors through the intratumoral generation of
heat via
activation of magnetic nanoparticles. NanoTherm®,
NanoPlan®, and
NanoActivator™ are components of the therapy and have received
EU-wide
regulatory approval as medical devices for the treatment of brain
tumors.
MagForce, NanoTherm®, NanoPlan®, and NanoActivator™ are
trademarks of
MagForce AG in select countries. For more information, please
visit
www.magforce.com : www.magforce.com .



Disclaimer



This release may contain forward-looking statements and information which
may be
identified by formulations using terms such as "expects", "aims",
"anticipates",
"intends", "plans", "believes", "seeks", "estimates" or "will". Such
forward-
looking statements are based on our current expectations and
certain
assumptions, which may be subject to a variety of risks and
uncertainties. The
results actually achieved by MagForce AG may substantially differ from
these
forward-looking statements. MagForce AG assumes no obligation to update
these
forward-looking statements or to correct them in case of developments,
which
differ from those, anticipated.



MagForce_Press Release_Jan 31, 2013:
hugin.info/143761/R/1674480/545259.pdf : hugin.info/143761/R/1674480/545259.pdf



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:



(i) the releases contained herein are protected by copyright and
other applicable laws; and



(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.



Source: MagForce AG via Thomson Reuters ONE
[HUG#1674480]




Contact:
Anne Hennecke
MC Services AG
T +49 89 210228-18
F +49 89 210228-88
M +49 151 12 555 759
Email: Email Contact : www2.marketwire.com/mw/emailprcntct?id=F7CCECAC33827C6E



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com